Handelsavisen
prelaunch
Companies Healthcare PRE.HN
PR
PRE.HN Pharmaceuticals & Medical Research

Pre.Hn

$26 100,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
7,02 %
Op margin
ROE
14,4 %
Net margin
Debt / equity
0,15
Beta
52w range
Volume
Day range
Prev close
$20,18
Open
$17,25
Next earnings
Ex-dividend
TR 1Y
About

PRE.HN operates in the reinsurance industry, providing risk transfer solutions to insurance companies by underwriting portions of their insurance liabilities.

Business. Prenetics Global Ltd (PRE.O) is a healthcare company operating in the biotechnology and medical research industry. The firm is headquartered in the United Kingdom and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target31,25

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
31,25
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
Goldman Sachs Asset Management, L.P.
largest disclosed fund holder
Profitability
14,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PRE.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PRE.HN. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Prenetics Global Ltd (PRE.O) is a healthcare company operating in the biotechnology and medical research industry. The firm is headquartered in the United Kingdom and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a free cash flow of 64,430,468,749.9999 VND and a debt-to-equity ratio of 0.15, indicating a relatively low reliance on debt financing. Its total assets amount to 7,461,524,730,460.0 VND, supported by a total equity of 1,666,718,923,760.0 VND, which suggests a solid capital base. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

    In terms of profitability, PRE.HN demonstrates a return on equity of 14.38% and a return on assets of 3.21%, which are key metrics for evaluating performance in the reinsurance industry. These figures suggest that the company is generating a healthy return for its shareholders, although the return on assets is relatively modest, indicating that asset utilization could be a focus area for improvement.

    The company's revenue is primarily concentrated in the reinsurance segment, with no significant geographic diversification disclosed in the available data. This concentration may expose the company to specific market risks, particularly in the regions where it operates.

    Looking at the growth trajectory, the company's operating income and net income have shown positive trends, with operating income at 79,245,049,840.0 VND and net income at 239,609,896,960.0 VND. However, the capital expenditure of -204,969,400.0 VND indicates a reduction in investment, which may affect long-term growth prospects.

    The risk assessment highlights a medium liquidity risk and a low dilution risk, with the key flag being the negative net cash position after total debt. The company's dilution potential is low, and no significant adjustments have been applied to the valuation metrics.

    Recent events and filings have not been disclosed in the available data, so there is no specific information on recent developments that could impact the company's performance.

    Key takeaways
    • PRE.HN has a strong liquidity position with a free cash flow of 64,430,468,749.9999 VND and a low debt-to-equity ratio of 0.15.
    • The company's return on equity of 14.38% indicates a healthy return for shareholders, although the return on assets of 3.21% suggests room for improvement in asset utilization.
    • Revenue is primarily concentrated in the reinsurance segment, with no significant geographic diversification disclosed.
    • The company's operating income and net income have shown positive trends, but the capital expenditure of -204,969,400.0 VND indicates a reduction in investment.
    • The risk assessment highlights a medium liquidity risk and a low dilution risk, with the key flag being the negative net cash position after total debt.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $26 100,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.67T
    Net cash
    -$242.00B
    Current ratio
    Debt / equity
    0.1
    ROA
    3.2%
    ROE
    14.4%
    Cash conversion
    201.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Consumer Health86,0 %
    disclosed · sec_xbrl · 2025-12-31

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)PRE 0,2% · rank #41 of 109

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs PRE · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    +73,8 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    -14,4 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    -126,8 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    +38,5 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    +52,3 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    -24,1 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Segment revenue · next quarter
    No quarterly segment estimate
    Segment data is reported at full-fiscal-year granularity only — no quarterly segment split is forecast (a quarterly figure is never inferred from the annual). See the full-fiscal-year segment-revenue card below.
    Full fiscal year~1 year ahead
    Segment-revenue forecast · full fiscal year · native currency
    • Consumer HealthFY2026 — next full year (forecast) · projected off FY2025 close, as of 2025-12-31 · conf —81,2MFORECAST
    • Consumer HealthFY2025 — reported · conf —5,7MREPORTED
    Model estimate of reported / forward segment revenue in issuer-native currency. Confidence shown where the model calibrated it; "—" where not (never inferred).
    Probabilistic model output — not investment advice. · generated 2026-06-25

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$29,00
    Mean$31,25
    Median$30,00
    High$36,00
    Spot$26 100,00
    −99.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE14,4 %Above P75
    D/E0,15Below median
    Cash Conv2,01Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 73 481 sh2 exercises · 2 grants3 insiders
    • VANDERVEEN DAVIDDirector · Restricted Stock Unit → Class A Ordinary Share, par value $0.0015 per shareDisposed 8 681exercise · 2026-06-15
    • Cheng Yin PanDirector · Restricted Stock Unit → Class A Ordinary Share, par value $0.0015 per shareDisposed 15 873exercise · 2026-06-15
    • Cheng Yin PanDirector · Restricted Stock Unit → Class A Ordinary Share, par value $0.0015 per shareAcquired 6 406grant · 2026-05-26
    • Lo Hoi ChunChief Financial Officer · Restricted Stock Unit → Class A Ordinary Share, par value $0.0015 per shareAcquired 91 629grant · 2026-05-19

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • PRE.HN Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$4M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$2M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Danny YeungChairman of the Board, Chief Executive Officer

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $02 insiders · last 365d
    • VANDERVEEN DAVIDDirector · Class A Ordinary Share, par value $0.0015 per shareOther 6 944 · 2026-06-15
    • Cheng Yin PanDirector · Class A Ordinary Share, par value $0.0015 per shareOther 15 873 · 2026-06-15

    Short positioning

    665.8Kshares short+19.4% vs prior
    2.48days to cover
    42.5%short of daily vol
    1.7Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PRE.HNCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
    2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
    2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
    2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
    2026-06-25 03:40 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-15 00:00 UTCINSIDER4 insider transactions — 2026-06 2 derivative
    2026-06-15INSIDERVANDERVEEN DAVID transacted 6.9k sh Class A Ordinary Share, par value $0.0015 per share — Director
    2026-06-15INSIDERCheng Yin Pan transacted 15.9k sh Class A Ordinary Share, par value $0.0015 per share — Director
    2026-06-15INSIDERCheng Yin Pan disposed of 15.9k sh Restricted Stock Unit — Director
    2026-06-15INSIDERVANDERVEEN DAVID disposed of 8.7k sh Restricted Stock Unit — Director
    2026-06-10FILING6-K filing →
    2026-06-04FILING6-K filing →
    2026-05-26 00:00 UTCINSIDER2 insider transactions — 2026-05 2 derivative
    2026-05-26INSIDERCheng Yin Pan acquired 6.4k sh Restricted Stock Unit — Director
    2026-05-20FILING6-K filing →
    2026-05-19INSIDERLo Hoi Chun acquired 91.6k sh Restricted Stock Unit — Chief Financial Officer
    2026-05-14FILING6-K filing →
    2026-05-14FILING6-K filing →
    2026-05-07FILING6-K filing →
    2026-05-04FILING6-K filing →
    2026-04-30FILING20-F filing →
    2026-04-02FILING6-K filing →
    2026-03-06FILING6-K filing →
    2026-03-03FILING6-K filing →
    2026-02-18FILING6-K filing →
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage